8/13/2019 SM Ranbaxy_Financial Analysis

1/12

Global Pharmaceutical Market by Region in 2011

Market Percentage

Europe 27.77

North America 36.32

Japan 11.64Latin America 6.98

Asia/Africa/Australia 17.29

Glob

Europe Nort

8/13/2019 SM Ranbaxy_Financial Analysis

2/12

28%

36%

12%

7%

17%

al Pharmaceutical Market by

Region in 2011

h America Japan Latin America Asia/Africa/Australia

8/13/2019 SM Ranbaxy_Financial Analysis

3/12

2008 2009 2010 2011

Net profit margin 0.116103526 -0.12587 0.041603 0.173924

Current Ratio 1.33 1.11 1.25 1.59

D/E ratio 1.49 1.09 0.92 0.78

Quick 0.7 0.69 0.7 0.99

inventory turnover 4.129 3.78 4.06 3.97

R&D/sales 10.86 10.9 9.48 6.29ROE

2008 2009 2010 2011

Sales 6776.28 7427.72 7467.65 8712.04

Profit after tax 786.75 -934.95 310.68 1515.23

Current liabilities & provisions 2177.14 4618.3 4163.86 4202.15

Marketable securities 131.45 445.05 417.49 716.15

Trade investments 19.96 343.54 334.44 327.85

Non-trade investments 112.24 248.25 206.35 392.27

Inventories 1640.86 1964.32 1840.7 2192.61

Receivables 2013.19 1994.93 2487.6 2499.46

Cash and bank balance 437.89 2395.64 1241.64 3264.44

Comments:1 D/E ratio of Ranbaxy has gone down over the years as can be see

Comments:2 R&D expenses % have gone down from 11% to 6% over a period

8/13/2019 SM Ranbaxy_Financial Analysis

4/12

n in the chart. Though it is still very high compared to oher pharamaceutical companies in India.Hence l

of four years. Actually it should increase because of the introduction of product patents in India.

0

2

4

6

8

10

12

14

2008 2009 2010 2011

D/E ratio

R&D/sales

Linear (D/E ratio)

Linear (R&D/sales

8/13/2019 SM Ranbaxy_Financial Analysis

5/12

everaging ma not be a feaible option and company hould look for profitable alliances to raise capital for

)

8/13/2019 SM Ranbaxy_Financial Analysis

6/12

investing in new manufacturing facilities.

8/13/2019 SM Ranbaxy_Financial Analysis

7/12

2008 2009 2010 2011

Net profit margin 0.16274 0.145225301 0.190643 0.151755 Mar-08

Current Ratio 1.99 1.72 2.27 2.07 Mar-08

D/E ratio 0.14 0.22 0.01 0.09 Mar-08

Quick 0.93 0.66 0.78 0.67 Mar-09

inventory turnover 1.151032 1316.603252 1.111816 1.28484 Mar-09ROCE 19.99 18.95 18.91 15.15 Mar-09

Mar-10

Mar-10

2008 2009 2010 2011 Mar-10

Net profit margin 0.084213 -0.126778087 0.047497 0.12609 Mar-11

Current Ratio 2.51 2.24 1.92 1.47 Mar-11

D/E ratio 0.44 0.57 0.39 0.59 Mar-11

Quick 1.41 1.31 1.07 0.85

inventory turnover 1.274798 1.689509434 1.435344 1.214545

ROCE 6.84 10.63 14.99 17.82

GSK Pharma

2008 2009 2010 2011

Net profit margin 0.304961 0.322913366 0.253085 0.249307

Current Ratio 0.97 1.29 1.55 1.53

D/E ratio 0 0 0 0

Quick 0.13 0.45 0.69 0.68

inventory turnover 1.551089 1.557472744 1.202176 1.117633

ROCE 29.25 40.76 29.49 30.41

Comment1: ROCE has been consitently low for Ranbaxy. T

Dr. Reddy

CIPLA

Com

8/13/2019 SM Ranbaxy_Financial Analysis

8/12

Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Glaxosmithkline Pharmaceuticals Ltd.

Sales 4307.72 5213 1795.44

RONW 19.97 10.33 29.38

ROCE 19.99 6.84 29.25

Sales 5309.13 7233.9 1830.46

RONW 19.09 15.74 40.91 ROCE 18.95 10.63 40.76

Sales 5678.62 7400.4 2006.68

RONW 19.02 22.04 29.59

ROCE 18.91 14.99 29.49

Sales 6372.97 7922.1 2248.51

RONW 15.29 24.53 30.49

ROCE 15.15 17.82 30.41

his can be attributed to the high D/E structure of company.

pany Name

-20

-10

0

10

20

30

40

50

ROCE ROCE ROCE ROCE

Mar-08 Mar-09 Mar-10 Mar-11

Cipla Ltd.

Dr. Reddy'S Laboratories Ltd.

Glaxosmithkline

Pharmaceuticals Ltd.

Ranbaxy Laboratories Ltd.

8/13/2019 SM Ranbaxy_Financial Analysis

9/12

Ranbaxy Laboratories Ltd.

6776.28

23.34

11.06

7427.72

-29.4-15.48

7467.65

5.12

2.96

8712.04

29.13

18.29

8/13/2019 SM Ranbaxy_Financial Analysis

10/12

Drugs India SriLanka Zimbawe UK US

Ciprofloxacin USD 0.81 1.16 1.5 11.4 37.88

500mg 10 Tablets INR 39 55.68 72 547.2 1818.24

Diclofenac Sodium USD 0.19 1.38 1.2 1.32 20.21

500mg 10 Tablets INR 9 66.24 57.6 63.36 970.08

8/13/2019 SM Ranbaxy_Financial Analysis

11/12

8/13/2019 SM Ranbaxy_Financial Analysis

12/12

Brand Market Share In the top 100 medicine list Ranbaxy has 9 products.

Cifran 28.1

Mox 42.9

Sporidex 45.5

Storvas 16.5

Zanocin 14.8Revital 90

Volini 17.3